This record was last updated January 13, 2026 (before its estimated March 24, 2026 completion). Its status may not reflect the trial's current state.
Summary
The trial uses a randomized, open-label, single-dose administration per period, and a 2 x 2 crossover design where subjects receive both treatments sequentially with a washout.